Ignite Creation Date:
2025-12-24 @ 6:51 PM
Ignite Modification Date:
2026-01-04 @ 12:01 AM
Study NCT ID:
NCT06026657
Status:
RECRUITING
Last Update Posted:
2025-07-08
First Post:
2023-08-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Sponsor:
Margaret Gatti-Mays
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-02
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-30
First Submit QC Date:
None
Study First Post Date:
2023-09-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-02
Last Update Post Date:
2025-07-08
Last Update Post Date Type:
ACTUAL